Abstract: A fermented extract of aerial parts of Citrus aurantium and the process for obtaining it. The fermented extract may be added to a cosmetic composition. Also, the use of a fermented extract of Citrus aurantium to combat skin ageing, and also as an antioxidant active agent, to prevent/reduce oxidative stress and/or to detoxify the skin.

Abstract: The present disclosure discloses a composition for skin anti-inflammation and skin moisturizing, which contains an Artemisia extract extracted using a skin cosmetic solution as an extraction solvent as an active ingredient. Specifically, the composition according to the present disclosure, which contains the Artemisia extract obtained using an effective and safe extraction solvent, may exhibit superior kin safety and usability as well as superior anti-inflammatory and moisturizing effects. In addition, the composition according to the present disclosure, which contains the Artemisia extract extracted using the skin cosmetic solution that can be used as a cosmetic ingredient as an extraction solvent, may superbly maintain Artemisia flavor without an additional flavoring agent.

Abstract: A skin treatment composition is described comprising a cryopreserved blend of natural materials including at least two components selected from the group consisting of wheat grass juice, wheat grass pulp, shea butter, cocoa powder, rice flour, coffee, jojoba oil, hemp oil, castor oil, and sugarcane juice. The skincare treatment composition is applied with a specialty applicator that is frozen into the compound during processing. Methods of making, packaging and using the compositions also are disclosed.

Abstract: This invention provides methods for extracting ingredients and materials from plant material, including extracting ingredients from cannabis plant material.

Abstract: The present disclosure is directed to a composition and method of enhancing skin health and appearance, as well as treating compromised skin, by applying onto the skin a composition containing a moisturizing/hydrating-effective amount of a mixture of at least: (a) an oil infusion of Calendula officinalis extract; (b) an oil infusion of Helichrysum italicum extract; (c) an oil infusion of Symphytum officinale extract; (d) an aqueous infusion of Viola tricolor extract; and (e) an aqueous infusion of at least one Mallow extract chosen from Malva sylvestris extract and Althea officinalis extract; and an emulsifying-effective amount of a dermatologically-acceptable emulsifier, wherein the composition is natural and free of a skin sensitizing-effective amount of an essential oil.

Abstract: A method of selecting a skin barrier system suitable for infants and young children is disclosed.

Abstract: The present disclosure provides compositions that enable sustained release of a small molecule tyrosine kinase inhibitor, such as axitinib from a bioerodible polyester polymer implant for the treatment of disease. The composition is especially suitable for treating ophthalmic indications, such as neovascular age related macular degeneration and diabetic macular edema, by intravitreal injection of the implant. The implant is designed to be pre-loaded into a small diameter needle and injected via self-sealing scleral needle penetration at the pars plana. Small molecule tyrosine kinase inhibitors may be released from the implants over a period of one week to three years.

Abstract: The disclosed technology provides an improved drug delivery device which is easily implantable and removable, as well as method of using and making the same. The described drug delivery device includes: (a) a wall comprising at least in part a polymeric composition, which surrounds and forms; (b) a compartment; (c) a drug composition in the compartment which includes an active agent; (d) at least one passageway in the wall for releasing the active agent from said drug composition to said environment of use. The device (i) can be implanted in an environment of use, (ii) is able to maintain its structural integrity for a period of use to allow for the release of the active agent, and (iii) can then be removed from the environment of use.

Abstract: The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with either a fatty acid or fatty alcohol and/or any other excipients, peptides, or nucleic acids. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may comprise a rod shape. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.

Abstract: It is provided a vaginal ring comprising a drug-loaded core comprising a progestogenic steroid compound, a estrogenic steroid compound, and an EVA copolymer having a vinyl acetate content from 25 to 35 wt. %, wherein the progestogenic steroid is dissolved in the core material in a relatively low degree of supersaturation; and a non-medicated outer layer of EVA copolymer having a vinyl acetate content from 5 to 15 wt. %; which is stable under storage at room temperature for at least 12 months. It is also provided a process for the preparation of the vaginal ring disclosed above.

Abstract: An animal treat composition for the oral administration of a medication to an animal is disclosed. The animal treat composition comprises an adhesive portion core and an outer portion. The adhesive portion adheres to oral medication inserted into the adhesive core of the treat for administration of the medication to an animal.

Abstract: The present invention relates to an anti-bacterial food additive and anti-bacterial food including the same, and more particularly, to an anti-bacterial food additive which includes a sintered silver-containing surface layer disposed on a base for a food additive, wherein the sintered silver includes silver sintered in a nitrogen atmosphere or silver oxide sintered in an oxygen atmosphere. In addition, anti-bacterial food including the anti-bacterial food additive has an excellent anti-bacterial effect.

Abstract: The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.

Abstract: Single-serve containers for use in brewing a cannabis-based beverage are described, as are methods for preparing a single-serve container configured for receipt in a single-serve brewing machine. The method includes: adding a processed cannabis product to the single-serve container; adding, to the single-serve container, at least one of an extraction or flavoring agent; and sealing the single-serve container.

Abstract: The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.

Abstract: An aqueous composition including-torasemide and at least one organic solvent, to a bottle or container including the composition, and to a kit including the bottle or container and a device for delivery of the composition (for example a syringe) A use of at least one organic solvent for increasing the stability and/or the antimicrobial properties of a composition including-torasemide. A method for preparing the composition.

Abstract: The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBF?-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.

Abstract: A method of delivering magnetic particles to a target site, including inserting a magnet catheter into a blood vessel; advancing the magnet catheter to a position downstream from the target site; and releasing magnetic particles into the blood vessel upstream of the target site; in which a first portion of the magnetic particles embolize in the blood vessel is disclosed. A system is also disclosed.

Abstract: An oral composition includes an immediate-release pharmaceutical admixture and an extended-release pharmaceutical admixture. The immediate-release pharmaceutical admixture includes a first portion of an active ingredient and a first portion of a hydrophilic dispersant, in which the active ingredient is substantially insoluble in water. The extended-release pharmaceutical admixture includes a controlled-release material, a second portion of the active ingredient, and a second portion of the hydrophilic dispersant, wherein the second portion of the active ingredient and the second portion of the hydrophilic dispersant are mixed in the controlled-release material, wherein the active ingredient is present as a nanoparticle in the immediate-release pharmaceutical admixture and the extended-release pharmaceutical admixture.

Abstract: The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 80-130 ?m. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3 months to 6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.

Abstract: A method for improving the dissolution profile of a biologically active material

Abstract: The present invention relates to an efficient production method of a medicament-containing particle. According to the present invention, it is possible to provide a method for producing a hollow particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, the method including a step of adding a polymer and a solvent capable of dissolving the polymer to a powder containing a medicament while rotating a container and a stirring blade by using a rotating mixing pan, and granulating the mixture by rotating the container and the stirring blade of the rotating mixing pan, wherein the polymer used as a starting material has an average particle size of not less than 5-fold that of the medicament used as a starting material.

Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.

Abstract: Described herein are alcohol-resistant oral pharmaceutical compositions and dosage forms that exhibit reduced drug release in the presence of alcohol. The compositions comprise a substrate comprising a controlled release formulation of lorazepam and an alcohol-resistant coating surrounding the substrate.

Abstract: An activated cannabinoid controlled release compound tablet and method of forming the same. In one embodiment, the tablet includes a cannabinoid and a hosting compound mixed with the cannabinoid to form a cannabinoid controlled release compound. The tablet may also include a surfactant mixed with the cannabinoid controlled release compound to form an activated cannabinoid controlled release compound.

Abstract: There is provided a method for producing a tablet having high tablet hardness without delaying the disintegration time. More specifically, there is provided a method for producing a tablet, including a granulation step of granulating a powder composition containing one or more of an active ingredient, an excipient and a disintegrant, while adding an aqueous composition containing a binder and water to the powder composition, to obtain a granulated product; and a heat treatment and tableting step of subjecting the granulated product to heat treatment and then tableting, or to tableting the granulated product and then heat treatment, to obtain a tablet.

Abstract: New soft capsules are described having within them a fill which contains thyroid hormones such as thyroxine T4 or triiodothyronine T3) and a high amylose-starch, optionally associated with vegetable hydrocolloids and/or glycerol. Compared to traditional capsules, these capsules have a strong and unexpected increase in the stability of T4 or T3 during storage.

Abstract: An object of the present disclosure is providing a hard capsule made of a hard capsule film having enteric properties that can be molded by a cold gel method. An enteric hard capsule comprises a film containing a first component and a second component, and further containing at least one component selected from the group consisting of a third component, a fourth component, and a fifth component, wherein the first component is a nonionic water-soluble cellulose compound having a viscosity value within a range of from 100 mPa·s to 100,000 mPa·s, the second component is an enteric methacrylic acid copolymer, the third component is an enteric cellulose compound, wherein the fourth component is a water-insoluble (meth)acrylic acid alkyl ester copolymer, and the fifth component is at least one kind selected from the group consisting of polyvinyl alcohol, a plasticizer, and a surfactant.

Abstract: The present invention is directed to a nanocrystal cannabidiol composition containing one or more lipids and one or more stabilizers. The present invention is further directed to a process of preparing a nanocrystal cannabidiol composition. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms comprising administering a composition of the present invention to a subject in need thereof.

Abstract: The present disclosure is directed to methods of producing lipid coated nanoparticles useful for biomedical applications, e.g., vaccines, adjuvants. The present disclosure is also directed in part to, e.g., multilamellar or unilamellar, protocell vaccines.

Abstract: The invention provides methods of treating a subject having diabetes mellitus. The invention further provides methods of increasing distribution volume of insulin in a subject.

Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Abstract: The present invention relates to matrix adhesive patch and its preparation. The present invention specifically relates to an analgesic matrix adhesive patch and its preparation. The present invention more specifically relates to a matrix patch adhesive preparation containing Camphor, Menthol and Methyl salicylate and process for the preparation thereof which delivers predetermined amount of drug continuously through skin and provide the temporary relief of minor aches & pains of muscles & joints associated with; Arthritis, Strains, Bruises & Sprains.

Abstract: Compositions and methods for reducing the symptoms of skin conditions associated with the nail and surrounding tissue are provided. A medicated pad for cleaning and treating the nail and surrounding tissue is described, wherein said pad is saturated with a therapeutic composition comprising certain botanicals, an antimicrobial agent, a surfactant, and a moisturizing agent. The skin and nail conditions can include fungal infections of the nails. Kits for treating fungal infections of the nails are likewise described. Optionally, the kit may include a hydrating composition which includes shea butter, aloe, vitamins, arnica, emu oil, urea, and Vitamins C, A, E, and D. A bandage comprising a therapeutic pad instilled with an antifungal agent is also provided.

Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Abstract: Embodiments relate to a method for treatment of blepharitis in a patient in need thereof comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically effective amount of at least one cannabinoid, via the topical route. Optionally, the pharmaceutical composition is administered in combination with an additional agent selected from the group consisting of: an essential oil, a steroid, an antibiotic, an anti-parasitic, a disinfectant, an anesthetic, a terpene, a moisturizer and a vitamin.

Abstract: The present disclosure relates to a bone graft material grafted with 4-hexylresorcinol affecting bone formation, the bone graft material which not only can rapidly promote bone formation by mixing hydrous ethanol having low concentration 4-hexylresorcinol dissolved therein and a base material for release control with distilled water or a salt-dissolved aqueous solution to obtain a mixed solution and precipitating a bone graft material into the mixed solution, thereby injecting 4-hexylresorcinol into the bone graft material, but also can have a consistent treatment effect by adjusting elution amount of 4-hexylresorcinol through the base material for release control, thereby allowing 4-hexylresorcinol to be slowly released during a treatment period.

Abstract: The present embodiments are directed to compositions comprising quillaja extract and at least one active ingredient such as nutritional supplement, dietary ingredient, medicine, and food additive, and methods for preparations and use thereof.

Abstract: The present invention relates to oral extended release composition, comprising memantine or its pharmaceutically acceptable salt as an active ingredient, resin complexation ingredient, release retardant, extended release coating system and the composition further comprising diluents, viscosity increasing agents, glidants, sweeteners, stabilizing agents, preservatives and other pharmaceutically acceptable excipients, wherein the drug-resin complex and drug-resin complex matrix particulates and coated drug-resin complex particulates have the specific particle size range. The present invention also relates to a process for the preparation of memantine or its salt oral extended release composition comprising the steps of drug-resin complexation, matrix resinate/particulates preparation process followed by extended release coating.

Abstract: The invention relates to a pre-filled syringe, an auto-injector device comprising such pre-filled syringe, a method of administering a pharmaceutical composition with such auto-injector device, and a manufacturing method for such auto-injector device. The pre-filled syringe comprises a container and a needle. The container is filled with a pharmaceutical composition comprising epinephrine, a buffer, and water. The buffer is configured to buffer in a pH range between 3 and 4. The needle is adhered to the container by means of a urethane acrylate or urethane methacrylate acrylic light cure adhesive, which is configured to provide a pull out resistance of the needle relative to the container which is between 30 N to 100 N, preferably between 50 N to 70 N, more preferably greater than 60 N after 90 days exposure to the pharmaceutical composition at 40° C. and 75% relative humidity (RH). In an example, the pharmaceutical composition is for the treatment of an anaphylactic event.

Abstract: Methods for treating Shiga toxicosis, caused by infection with Shiga toxin bacteria, are provided. The methods include administering to a subject in need thereof an effective amount of one or more active agents selected from tamoxifen, 4-hydroxytamoxifen, endoxifen, toremifene, raloxifene, bazedoxifene, and pharmaceutically acceptable salts thereof. In some embodiments, the methods further include the administration of an antibiotic or a manganese compound to the subject. Pharmaceutical compositions for the treatment of Shiga toxicosis are also described.

Abstract: Compounds useful in inhibiting endo-exonuclease activity and treating cancer have the formula (I) wherein R3 is selected from the group consisting of loweralkyl, oxyalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aminoalkyl or a halogen; R4 is selected from the group consisting of H, loweralkyl, oxyalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aminoalkyl or a halogen; and wherein R5 is a loweralkyl; or formula (II) wherein R1 is selected from the group consisting of loweralkyl, oxyalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aminoalkyl or halogen; R2 is selected from the group consisting of H, loweralkyl, oxyalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aminoalkyl or halogen; and wherein R5 is a loweralkyl comprising a linear carbon chain of at least two carbons connecting the first “O” to the second “O”.

Abstract: Described herein are compositions comprising capsaicin and methods of treating muscle cramping in a subject, comprising orally administering to the subject a composition comprising capsaicin and an excipient.

Abstract: The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 ?g to 3000 ?g.

Abstract: Beta-hydroxybutyrate (BHB) mixed salts are formulated to induce or sustain ketosis in a subject. The BHB mixed salts provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. BHB mixed salt compositions include two, three or four of sodium BHB, potassium BHB, calcium BHB, or magnesium BHB. BHB mixed salt compositions include R—BHB and/or S-BHB, such as enriched with either R-BHB or S-BHB. BHB mixed salt compositions may include BHB mixed salts and beta-hydroxybutyric acid. BHB mixed salts may be provided as or mixed with a dietetically or pharmaceutically acceptable carrier. BHB mixed salt compositions can be a solid, such as a powder, or a liquid, such as a beverage. A mixed salt-acid composition is particularly well-suited for flavored beverages.

Abstract: Methods are disclosed for the use of GC-1 (sobetirome), a prodrug thereof, or a pharmaceutically acceptable salt or prodrug thereof to increase liver regeneration and healing in liver transplant donors and recipients.

Abstract: Among the various aspects of the present disclosure is the provision of composition comprising itaconate, malonate, n or a derivative thereof and uses thereof. The present disclosure provides for methods of treating Ikb-? associated disease, disorder, or conditions comprising administering a therapeutically effective amount of an itaconate, malonate, or a derivative thereof to a subject. In some embodiments, the therapeutically effective amount reduces or prevents tumor growth, inflammation, or an immune response. Another aspect of the present disclosure includes a method to suppress Ikb-? induction comprising administering an itaconate, malonate, or a derivative thereof.

Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.

Abstract: The present invention relates to pathogenic bacteria, and is particularly concerned with treating, preventing or ameliorating bacterial infections using novel antibiotic compositions. The invention is especially useful for treating infections of Bacillus and Clostridia species, such as Clostridium difficile, Staphylococcus aureus and Mycobacterium spp. The invention extends to pharmaceutical compositions comprising such formulations. The invention also extends to methods for identifying aerobic Bacillus spp., which exhibit antibacterial activity against other bacteria, such as C. difficile, and to methods for isolating active antibacterial compositions from these aerobic Bacillus spp.

Abstract: The present invention relates to liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable liquid pharmaceutical compositions of baclofen at concentrations of 5 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and stable at pH ranges of 5-8 over a variety of storage conditions, including long-term storage for extended periods of time.